Format

Send to

Choose Destination
Semin Cancer Biol. 2008 Dec;18(6):381-7. doi: 10.1016/j.semcancer.2008.10.002. Epub 2008 Oct 19.

Immune escape by Epstein-Barr virus associated malignancies.

Author information

1
Viral Immunobiology, Institute of Experimental Immunology, University Hospital of Zurich, Zurich, Switzerland. christian.muenz@usz.ch

Abstract

Persistent Epstein-Barr virus (EBV) infection remains asymptomatic in the majority of virus carriers, despite the potent growth transforming potential of this virus. The increased frequency of EBV associated B cell lymphomas in immune compromised individuals suggests that tumor-free chronic infection with this virus is in part due to immune control. Here we discuss the evidence that loss of selective components of EBV specific immunity might contribute to EBV associated malignancies, like nasopharyngeal carcinoma, Burkitt's and Hodgkin's lymphoma, in otherwise immune competent patients. Furthermore, we discuss how current vaccine approaches against EBV might be able to target these selective deficiencies.

PMID:
18996483
PMCID:
PMC2615476
DOI:
10.1016/j.semcancer.2008.10.002
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center